Yahoo

3 European Stocks Estimated To Be Trading Up To 39.9% Below Intrinsic Value

As European markets experience volatility, with the pan-European STOXX Europe 600 Index hitting a new high before ending the week broadly unchanged, investors are navigating concerns about AI disruption and interpreting strong U.S. jobs data. In this environment, identifying stocks trading below their intrinsic value can be a prudent strategy for those looking to capitalize on potential market inefficiencies.

Top 10 Undervalued Stocks Based On Cash Flows In Europe

Name

Current Price

Fair Value (Est)

Discount (Est)

Troax Group (OM:TROAX)

SEK95.60

SEK189.08

49.4%

Palfinger (WBAG:PAL)

€39.80

€78.37

49.2%

Neste Oyj (HLSE:NESTE)

€20.75

€41.08

49.5%

Lectra (ENXTPA:LSS)

€20.05

€40.09

50%

Grieg Seafood (OB:GSF)

NOK72.40

NOK143.53

49.6%

Galderma Group (SWX:GALD)

CHF152.20

CHF299.37

49.2%

Endúr (OB:ENDUR)

NOK102.20

NOK200.06

48.9%

Circle (BIT:CIRC)

€8.98

€17.60

49%

B&S Group (ENXTAM:BSGR)

€5.85

€11.66

49.8%

Boreo Oyj (HLSE:BOREO)

€16.50

€32.67

49.5%

Click here to see the full list of 195 stocks from our Undervalued European Stocks Based On Cash Flows screener.

Let's take a closer look at a couple of our picks from the screened companies.

Outokumpu Oyj

Overview:Outokumpu Oyj is a global producer and seller of stainless steel products, operating in multiple regions including Europe, North America, and the Asia-Pacific, with a market cap of €2.39 billion.

Operations:The company's revenue segments include stainless steel products sold across Finland, Germany, Italy, the United Kingdom, other European countries, North America, and the Asia-Pacific.

Estimated Discount To Fair Value:35.6%

Outokumpu Oyj trades at €5.08, significantly below its estimated future cash flow value of €7.89, suggesting undervaluation. Despite a forecasted annual profit growth above market averages and expected profitability within three years, the company faces challenges with low return on equity projections and slower revenue growth compared to peers. Recent restructuring aims for €100 million in cost savings by 2027 amidst weak demand and competition pressures, impacting approximately 650 positions across Europe.

HLSE:OUT1V Discounted Cash Flow as at Feb 2026
HLSE:OUT1V Discounted Cash Flow as at Feb 2026

Nokian Renkaat Oyj

Overview:Nokian Renkaat Oyj is a company that develops and manufactures tires for passenger cars, trucks, and heavy machinery across the Nordics, Europe, the Americas, and other international markets with a market cap of €1.56 billion.

Operations:The company's revenue segments consist of €363.80 million from Vianor, €232 million from Heavy Tyres, and €858.40 million from Passenger Car Tyres.

Estimated Discount To Fair Value:28.6%

Nokian Renkaat Oyj, trading at €11.33, is undervalued relative to its future cash flow estimate of €15.87, with a significant discount over 20%. Despite low forecasted return on equity and interest payments not well covered by earnings, the company anticipates profitability in three years with above-average profit growth. Recent developments include new product innovations like the Nokian Tyres Betula concept tire and strategic leadership changes as it targets sustainable growth and increased use of renewable materials.

HLSE:TYRES Discounted Cash Flow as at Feb 2026
HLSE:TYRES Discounted Cash Flow as at Feb 2026

Bonesupport Holding

Overview:Bonesupport Holding AB (publ) is an orthobiologics company that develops and sells injectable bio-ceramic bone graft substitutes across Europe, North America, and internationally, with a market cap of SEK11.91 billion.

Operations:The company generates revenue primarily from its Pharmaceuticals segment, which amounted to SEK1.12 billion.

Estimated Discount To Fair Value:39.9%

Bonesupport Holding is trading at SEK180.8, significantly below its estimated future cash flow value of SEK300.72, indicating substantial undervaluation. The company forecasts robust revenue growth above 35% for 2026 and anticipates earnings to grow significantly over the next three years. Recent regulatory developments involve transitioning CERAMENT V's FDA application to the De Novo process, potentially establishing a new product category and impacting market positioning positively if successful.

OM:BONEX Discounted Cash Flow as at Feb 2026
OM:BONEX Discounted Cash Flow as at Feb 2026

Where To Now?

Searching for a Fresh Perspective?

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Companies discussed in this article include HLSE:OUT1V HLSE:TYRES and OM:BONEX.

This article was originally published by Simply Wall St .

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com

Mobilize your Website
View Site in Mobile | Classic
Share by: